Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

US cardiovascular centres set to report on the capabilities of InfraReDx’s LipiScan System

InfraReDx : 10 October, 2008  (Company News)
Five leading cardiovascular centres in the USA have adopted InfraReDx’s LipiScan System to identify lipid core containing coronary plaques and used the system for routine clinical care in over 50 patients undergoing coronary artery disease stenting procedures.
Physicians from the centres will report on their initial experience with the device in multiple presentations at the Transcatheter Cardiovascular Therapeutics (TCT) Conference to be held in Washington DC from October 12 to 16, 2008. The TCT is the world's leading meeting for those performing coronary diagnostics and stenting.

The system permits the performance of spectroscopy, which is widely used to determine chemical composition of unknown materials, to be performed inside the coronary artery of a living patient.

Dr Craig M Gardner, director of algorithm development at InfraReDx and lead author of the validation manuscript explained that: 'NIR spectroscopy is sensitive to the chemical composition of tissue, can penetrate through several millimetres of blood, and can collect measurements rapidly through thin and flexible optical fibres.'

'The InfraReDx team is pleased that the LipiScan System has been validated in tissue samples and a clinical study and has been cleared by the FDA for use in patients. We understand the great potential of interventional cardiology and anticipate that this novel tool will assist physicians with the complex decisions they face in the management of patients with coronary artery disease,' said James E Muller, MD, cardiologist, co-founder and chief executive officer of InfraReDx.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo